Context Therapeutics (CNTX) Corporate presentation summary

Strategic focus and pipeline development

• Advancing a pipeline of T cell engagers (TCEs) targeting solid tumors with high unmet need and large patient populations.

• Lead assets include CTIM-76 (CLDN6 x CD3), CT-95 (MSLN x CD3), and CT-202 (Nectin-4 x CD3), each designed for high selectivity and safety.

• Each program targets antigens validated by ADC or CAR-T therapies and addresses indications with limited competition.

• Strong financial position with cash runway expected into mid-2027.

Clinical pipeline and differentiation

• CTIM-76 targets CLDN6, overexpressed in ovarian, endometrial, lung, and testicular cancers; Phase 1a interim data expected June 2026.

• CT-95 targets MSLN, prevalent in pancreatic, lung, colorectal, and ovarian cancers; Phase 1a interim data expected September 2026.

• CT-202 targets Nectin-4, found in bladder, lung, breast, and colorectal cancers; first patient dosing in Phase 1 expected Q3 2026.

• Each asset incorporates design features to maximize tumor selectivity and minimize off-target effects.

Mechanism of action and innovation

• TCEs are bispecific antibodies that redirect cytotoxic T cells to tumor cells by binding both a tumor antigen and CD3.

• CTIM-76 uses a highly selective CLDN6 binder and monovalent CD3 scFv to avoid off-target activation and cytokine release.

• CT-95 is engineered to bind membrane-bound MSLN, overcoming the challenge of shed MSLN fragments in the tumor microenvironment.

• CT-202 employs pH-dependent binding and avidity optimization to enhance tumor selectivity and reduce skin toxicity.